Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012.

Letter to Our Readers.

The future of JAK inhibition in myelofibrosis and beyond.

BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies.

Variability of individual platelet reactivity over time in patients treated with clopidogrel: insights from the ELEVATE-TIMI 56 trial.

Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients.

Assessing disease burden in patients with classic MPNs.

Janus kinase inhibitors for the treatment of myeloproliferative neoplasms.

Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union.

CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo.